An analytical study of Trastuzumab-dendrimer-fluorine drug delivery system in breast cancer therapy in vitro - 19/12/20
páginas | 11 |
Iconografías | 13 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | Drug delivery is a critical step in the application of new immunotherapies to treat breast cancer. |
• | Three-dimensional breast cancer cell cultures are suitable for in vitro drug monitoring in MRI scanner. |
• | Trastuzumab-dendrimer-fluorine drug delivery system efficacy can be evaluated in 3D breast cell culture at 1.5 T. |
Abstract |
Trastuzumab is considered to be a fundamental drug for treatment of breast cancer with Her-2 overexpression (Her-2 positive cells). Trastuzumab is a monoclonal antibody that targets the Her-2 receptor. Trastuzumab treatment used in breast cancer therapy require a visualization to validate their delivery and response. The objective of this study was to investigate Trastuzumab-dendrimer-fluorine drug delivery system by synthesis and characterization of a series of fluorinated dendrimers.
Materials and methods |
Trastuzumab-dendrimer-fluorine drug delivery system is a covalent attachment of Trastuzumab to fluorinated dendrimers. We design synthesis and evaluate main product by using electrophoresis, HPLC and LC–MS techniques. We prepared three-dimensional breast cancer cell culture in bioreactor device. For the cell culture we used MCF-7 cells with Her-2 overexpression to study Trastuzumab-dendrimer-fluorine drug delivery system efficacy. We evaluate efficacy by Magnetic Resonance Imaging (MRI) relaxation time.
Results |
An analytical analysis showed that synthesis of Trastuzumab-dendrimer-fluorine drug delivery system is possible to obtain with a good yield. The results obtained indicated potential of Trastuzumab-dendrimer-fluorine drug delivery system is more efficient than trastuzumab alone. Chromatographic and electrophoretic separations showed that the synthetized conjugates were a Trastuzumab-dendrimer-fluorine drug delivery systems. The hight synthesis efficiency was found. The presence of molecules with lower masses than trastuzumab can have influence on efficiency.
Conclusions |
Trastuzumab-dendrimer-fluorine drug delivery system is a new form of Trastuzumab to treat breast cancer cells in vitro. Due to presence of 19F nuclei the system can be monitored by MRI measurements.
El texto completo de este artículo está disponible en PDF.Keywords : Trastuzumab, Drug delivery system, Electrophoresis, Chromatography, MRI
Esquema
Vol 133
Artículo 111053- janvier 2021 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?